Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 83

1.

Genomic characterization of hepatitis C virus transmitted founder variants with deep sequencing.

Abayasingam A, Leung P, Eltahla A, Bull RA, Luciani F, Grebely J, Dore GJ, Applegate T, Page K, Bruneau J, Cox AL, Kim AY, Schinkel J, Shoukry NH, Lauer GM, Maher L, Hellard M, Prins M, Lloyd A, Rodrigo C; InC3 Study Group.

Infect Genet Evol. 2019 Mar 8;71:36-41. doi: 10.1016/j.meegid.2019.02.032. [Epub ahead of print]

PMID:
30853512
2.

Sex discrepancies in the protective effect of opioid agonist therapy on incident hepatitis C infection.

Geddes L, Iversen J, Wand H, Esmaeili A, Tsui J, Hellard M, Dore G, Grebely J, Dietze P, Bruneau J, Prins M, Morris MD, Shoukry NH, Lloyd AR, Kim AY, Lauer G, Cox AL, Page K, Maher L; InC3 Collaborative.

Clin Infect Dis. 2019 Feb 28. pii: ciz162. doi: 10.1093/cid/ciz162. [Epub ahead of print]

PMID:
30816419
3.

Differential contribution of education through KIR2DL1, KIR2DL3, and KIR3DL1 to antibody-dependent (AD) NK cell activation and ADCC.

Lisovsky I, Kant S, Tremblay-McLean A, Isitman G, Kiani Z, Dupuy FP, Gilbert L, Bruneau J, Shoukry NH, Lebouché B, Bernard NF.

J Leukoc Biol. 2019 Mar;105(3):551-563. doi: 10.1002/JLB.4A0617-242RRR. Epub 2019 Jan 30.

PMID:
30698860
4.

Genomic variability of within-host hepatitis C variants in acute infection.

Rodrigo C, Leung P, Lloyd AR, Bull RA, Luciani F, Grebely J, Dore GJ, Applegate T, Page K, Bruneau J, Cox AL, Osburn W, Kim AY, Shoukry NH, Lauer GM, Maher L, Schinkel J, Prins M, Hellard M, Eltahla AA; InC3 Collaborative.

J Viral Hepat. 2019 Apr;26(4):476-484. doi: 10.1111/jvh.13051. Epub 2019 Jan 22.

PMID:
30578702
5.

Type 3 cytokines IL-17A and IL-22 drive TGF-β-dependent liver fibrosis.

Fabre T, Molina MF, Soucy G, Goulet JP, Willems B, Villeneuve JP, Bilodeau M, Shoukry NH.

Sci Immunol. 2018 Oct 26;3(28). pii: eaar7754. doi: 10.1126/sciimmunol.aar7754.

PMID:
30366940
6.

Longitudinal transcriptomic characterization of the immune response to acute hepatitis C virus infection in patients with spontaneous viral clearance.

Rosenberg BR, Depla M, Freije CA, Gaucher D, Mazouz S, Boisvert M, Bédard N, Bruneau J, Rice CM, Shoukry NH.

PLoS Pathog. 2018 Sep 17;14(9):e1007290. doi: 10.1371/journal.ppat.1007290. eCollection 2018 Sep.

7.

Type 3 cytokines in liver fibrosis and liver cancer.

Molina MF, Abdelnabi MN, Fabre T, Shoukry NH.

Cytokine. 2018 Aug 7. pii: S1043-4666(18)30326-0. doi: 10.1016/j.cyto.2018.07.028. [Epub ahead of print]

PMID:
30097286
8.

Hepatitis C Vaccines, Antibodies, and T Cells.

Shoukry NH.

Front Immunol. 2018 Jun 28;9:1480. doi: 10.3389/fimmu.2018.01480. eCollection 2018. Review.

9.

Interleukin-10 Directly Inhibits CD8+ T Cell Function by Enhancing N-Glycan Branching to Decrease Antigen Sensitivity.

Smith LK, Boukhaled GM, Condotta SA, Mazouz S, Guthmiller JJ, Vijay R, Butler NS, Bruneau J, Shoukry NH, Krawczyk CM, Richer MJ.

Immunity. 2018 Feb 20;48(2):299-312.e5. doi: 10.1016/j.immuni.2018.01.006. Epub 2018 Jan 23.

10.

CCDC88B is required for pathogenesis of inflammatory bowel disease.

Fodil N, Moradin N, Leung V, Olivier JF, Radovanovic I, Jeyakumar T, Flores Molina M, McFarquhar A, Cayrol R, Bozec D, Shoukry NH, Kubo M, Dimitrieva J, Louis E, Theatre E, Dahan S, Momozawa Y, Georges M, Yeretssian G, Gros P.

Nat Commun. 2017 Oct 13;8(1):932. doi: 10.1038/s41467-017-01381-y.

11.

The Effect of Female Sex on Hepatitis C Incidence Among People Who Inject Drugs: Results From the International Multicohort InC3 Collaborative.

Esmaeili A, Mirzazadeh A, Morris MD, Hajarizadeh B, Sacks HS, Maher L, Grebely J, Kim AY, Lauer G, Cox AL, Hellard M, Dietze P, Bruneau J, Shoukry NH, Dore GJ, Lloyd AR, Prins M, Page K; InC3 Collaborative.

Clin Infect Dis. 2018 Jan 6;66(1):20-28. doi: 10.1093/cid/cix768.

12.

Type 2 immunity is protective in metabolic disease but exacerbates NAFLD collaboratively with TGF-β.

Hart KM, Fabre T, Sciurba JC, Gieseck RL 3rd, Borthwick LA, Vannella KM, Acciani TH, de Queiroz Prado R, Thompson RW, White S, Soucy G, Bilodeau M, Ramalingam TR, Arron JR, Shoukry NH, Wynn TA.

Sci Transl Med. 2017 Jun 28;9(396). pii: eaal3694. doi: 10.1126/scitranslmed.aal3694.

PMID:
28659437
13.

Geographic Differences in Temporal Incidence Trends of Hepatitis C Virus Infection Among People Who Inject Drugs: The InC3 Collaboration.

Morris MD, Shiboski S, Bruneau J, Hahn JA, Hellard M, Prins M, Cox AL, Dore G, Grebely J, Kim AY, Lauer GM, Lloyd A, Rice T, Shoukry N, Maher L, Page K; International Collaboration of Incident HIV and HCV in Injecting Cohorts (InC3).

Clin Infect Dis. 2017 Apr 1;64(7):860-869. doi: 10.1093/cid/ciw869. Erratum in: Clin Infect Dis. 2017 Aug 15;65(4):706-707.

14.

Selective expansion of high functional avidity memory CD8 T cell clonotypes during hepatitis C virus reinfection and clearance.

Abdel-Hakeem MS, Boisvert M, Bruneau J, Soudeyns H, Shoukry NH.

PLoS Pathog. 2017 Feb 1;13(2):e1006191. doi: 10.1371/journal.ppat.1006191. eCollection 2017 Feb.

15.

Type III Interferons in Hepatitis C Virus Infection.

Boisvert M, Shoukry NH.

Front Immunol. 2016 Dec 23;7:628. doi: 10.3389/fimmu.2016.00628. eCollection 2016. Review.

16.

Limited naturally occurring escape in broadly neutralizing antibody epitopes in hepatitis C glycoprotein E2 and constrained sequence usage in acute infection.

Rodrigo C, Walker MR, Leung P, Eltahla AA, Grebely J, Dore GJ, Applegate T, Page K, Dwivedi S, Bruneau J, Morris MD, Cox AL, Osburn W, Kim AY, Schinkel J, Shoukry NH, Lauer GM, Maher L, Hellard M, Prins M, Luciani F, Lloyd AR, Bull RA; InC(3) Study Group.

Infect Genet Evol. 2017 Apr;49:88-96. doi: 10.1016/j.meegid.2017.01.006. Epub 2017 Jan 5.

17.

Restrictions for reimbursement of direct-acting antiviral treatment for hepatitis C virus infection in Canada: a descriptive study.

Marshall AD, Saeed S, Barrett L, Cooper CL, Treloar C, Bruneau J, Feld JJ, Gallagher L, Klein MB, Krajden M, Shoukry NH, Taylor LE, Grebely J; Canadian Network on Hepatitis C (CanHepC).

CMAJ Open. 2016 Oct 14;4(4):E605-E614. doi: 10.9778/cmajo.20160008. eCollection 2016 Oct-Dec.

18.

Novel E2 Glycoprotein Tetramer Detects Hepatitis C Virus-Specific Memory B Cells.

Boisvert M, Zhang W, Elrod EJ, Bernard NF, Villeneuve JP, Bruneau J, Marcotrigiano J, Shoukry NH, Grakoui A.

J Immunol. 2016 Dec 15;197(12):4848-4858. Epub 2016 Nov 14.

19.

The effects of alcohol on spontaneous clearance of acute hepatitis C virus infection in females versus males.

Tsui JI, Mirzazadeh A, Hahn JA, Maher L, Bruneau J, Grebely J, Hellard M, Kim AY, Shoukry NH, Cox AL, Prins M, Dore GJ, Lauer G, Lloyd AR, Page K.

Drug Alcohol Depend. 2016 Dec 1;169:156-162. doi: 10.1016/j.drugalcdep.2016.10.024. Epub 2016 Oct 26.

20.

Phylogenetic analysis of full-length, early infection, hepatitis C virus genomes among people with intravenous drug use: the InC3 Study.

Rodrigo C, Eltahla AA, Bull RA, Luciani F, Grebely J, Dore GJ, Applegate T, Page K, Bruneau J, Morris MD, Cox AL, Osburn W, Kim AY, Shoukry NH, Lauer GM, Maher L, Schinkel J, Prins M, Hellard M, Lloyd AR; InC3 Collaborative.

J Viral Hepat. 2017 Jan;24(1):43-52. doi: 10.1111/jvh.12616. Epub 2016 Nov 3.

Supplemental Content

Loading ...
Support Center